Cross-talk between the complement and the kinin system in vascular permeability

Immunology Letters

Volumn 140, Issue 1-2, 2011, Pages 7-13

  Bossi, Fleur ^a   Peerschke, Ellinor I ^b   Ghebrehiwet, Berhane ^c   Tedesco, Francesco ^a  

^a UNIVERSITY OF TRIESTE   (Italy)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^c STONY BROOK UNIVERSITY   (United States)

Author keywords

Angioedema; C1 inhibitor; Complement; Endothelium; GC1qR p33; Kinins

Indexed keywords

BRADYKININ; BRADYKININ B2 RECEPTOR; C1Q RECEPTOR; COMPLEMENT COMPONENT C1Q; KININOGEN; PREKALLIKREIN; PROTEIN P33; UNCLASSIFIED DRUG;

ANGIONEUROTIC EDEMA; BINDING AFFINITY; BLOOD VESSEL PERMEABILITY; COMPLEMENT ACTIVATION; COMPLEMENT CLASSICAL PATHWAY; COMPLEMENT SYSTEM; COMPLEX FORMATION; DISEASE MODEL; HUMAN; IMMUNE RESPONSE; IMMUNOPATHOGENESIS; INNATE IMMUNITY; KALLIKREIN KININ SYSTEM; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN SECRETION; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; BRADYKININ; CAPILLARY PERMEABILITY; COMPLEMENT ACTIVATION; COMPLEMENT SYSTEM PROTEINS; HEREDITARY ANGIOEDEMA TYPES I AND II; HUMANS; MOLECULAR TARGETED THERAPY; RECEPTOR CROSS-TALK; RECEPTORS, BRADYKININ;

EID: 80051799733     PISSN: 01652478     EISSN: 18790542     Source Type: Journal    
DOI: 10.1016/j.imlet.2011.06.006     Document Type: Review

References (73)

1. Cines D.B., Pollak E.S., Buck C.A., Loscalzo J., Zimmerman G.A., McEver R.P., et al. Endothelial cells in physiology and in the pathophysiology of vascular disorders. Blood 1998, 91:3527-3561.
2. Laufer J., Katz Y., Passwell J.H. Extrahepatic synthesis of complement proteins in inflammation. Mol Immunol 2001, 38:221-229.
3. Langeggen H., Pausa M., Johnson E., Casarsa C., Tedesco F. The endothelium is an extrahepatic site of synthesis of the seventh component of the complement system. Clin Exp Immunol 2000, 121:69-76.
4. Bossi F., Rizzi L., Bulla R., Debeus A., Tripodo C., Picotti P., et al. C7 is expressed on endothelial cells as a trap for the assembling terminal complement complex and may exert anti-inflammatory function. Blood 2009, 113:3640-3648.
5. Fischetti F., Durigutto P., Pellis V., Debeus A., Macor P., Bulla R., et al. Thrombus formation induced by antibodies to beta2-glycoprotein I is complement dependent and requires a priming factor. Blood 2005, 106:2340-2346.
6. Girardi G., Bulla R., Salmon J.E., Tedesco F. The complement system in the pathophysiology of pregnancy. Mol Immunol 2006, 43:68-77.
7. Collard C.D., Montalto M.C., Reenstra W.R., Buras J.A., Stahl G.L. Endothelial oxidative stress activates the lectin complement pathway: role of cytokeratin 1. Am J Pathol 2001, 159:1045-1054.
8. Ricklin D., Hajishengallis G., Yang K., Lambris J.D. Complement: a key system for immune surveillance and homeostasis. Nat Immunol 2010, 11:785-797.
9. Collard C.D., Vakeva A., Morrissey M.A., Agah A., Rollins S.A., Reenstra W.R., et al. Complement activation after oxidative stress: role of the lectin complement pathway. Am J Pathol 2000, 156:1549-1556.
10. Moller-Kristensen M., Wang W., Ruseva M., Thiel S., Nielsen S., Takahashi K., et al. Mannan-binding lectin recognizes structures on ischaemic reperfused mouse kidneys and is implicated in tissue injury. Scand J Immunol 2005, 61:426-434.
11. Wallis R., Mitchell D.A., Schmid R., Schwaeble W.J., Keeble A.H. Paths reunited: initiation of the classical and lectin pathways of complement activation. Immunobiology 2010, 215:1-11.
12. Peerschke E.I., Malhotra R., Ghebrehiwet B., Reid K.B., Willis A.C., Sim R.B. Isolation of a human endothelial cell C1q receptor (C1qR). J Leukoc Biol 1993, 53:179-184.
13. Peerschke E.I., Smyth S.S., Teng E.I., Dalzell M., Ghebrehiwet B. Human umbilical vein endothelial cells possess binding sites for the globular domain of C1q. J Immunol 1996, 157:4154-4158.
14. Lozada C., Levin R.I., Huie M., Hirschhorn R., Naime D., Whitlow M., et al. Identification of C1q as the heat-labile serum cofactor required for immune complexes to stimulate endothelial expression of the adhesion molecules E-selectin and intercellular and vascular cell adhesion molecules 1. Proc Natl Acad Sci USA 1995, 92:8378-8382.
15. van den Berg R.H., Faber-Krol M.C., Sim R.B., Daha M.R. The first subcomponent of complement, C1q, triggers the production of IL-8, IL-6, and monocyte chemoattractant peptide-1 by human umbilical vein endothelial cells. J Immunol 1998, 161:6924-6930.
16. Ratnoff O.D., Lepow I.H. Complement as a mediator of inflammation enhancement of vascular permeability by purified human C'1 esterase. J Exp Med 1963, 118:681-698.
17. Strang C.J., Auerbach H.S., Rosen F.S. C1s-induced vascular permeability in C2-deficient guinea pigs. J Immunol 1986, 137:631-635.
18. Fields T., Ghebrehiwet B., Kaplan A.P. Kinin formation in hereditary angioedema plasma: evidence against kinin derivation from C2 and in support of " spontaneous" formation of bradykinin. J Allergy Clin Immunol 1983, 72:54-60.
19. Van Beek J., Bernaudin M., Petit E., Gasque P., Nouvelot A., MacKenzie E.T., et al. Expression of receptors for complement anaphylatoxins C3a and C5a following permanent focal cerebral ischemia in the mouse. Exp Neurol 2000, 161:373-382.
20. Monsinjon T., Gasque P., Chan P., Ischenko A., Brady J.J., Fontaine M.C. Regulation by complement C3a and C5a anaphylatoxins of cytokine production in human umbilical vein endothelial cells. FASEB J 2003, 17:1003-1014.
21. Schraufstatter I.U., Trieu K., Sikora L., Sriramarao P., DiScipio R. Complement c3a and c5a induce different signal transduction cascades in endothelial cells. J Immunol 2002, 169:2102-2110.
22. Miyama K., Takano K., Atsumi I., Nakagawa H. Identification of C3a and N-truncated C3a as vascular permeability-enhancing factors from the exudate of chronic phase of carrageenan-induced inflammation in rats. Biol Pharm Bull 2002, 25:648-651.
23. Lister K.J., James W.G., Hickey M.J. Immune complexes mediate rapid alterations in microvascular permeability: roles for neutrophils, complement, and platelets. Microcirculation 2007, 14:709-722.
24. Nitta H., Imamura T., Wada Y., Irie A., Kobayashi H., Okamoto K., et al. Production of C5a by ASP, a serine protease released from Aeromonas sobria. J Immunol 2008, 181:3602-3608.
25. Liu Z.M., Zhu S.M., Qin X.J., Cheng Z.D., Liu M.Y., Zhang H.M., et al. Silencing of C5a receptor gene with siRNA for protection from Gram-negative bacterial lipopolysaccharide-induced vascular permeability. Mol Immunol 2010, 47:1325-1333.
26. Tedesco F., Bulla R., Fischetti F. Terminal complement complex: regulation of formation and pathophysiological functions. The complement system 2004, 97-127. KAP. J. DSzebeni (Ed.).
27. Bossi F., Fischetti F., Pellis V., Bulla R., Ferrero E., Mollnes T.E., et al. Platelet-activating factor and kinin-dependent vascular leakage as a novel functional activity of the soluble terminal complement complex. J Immunol 2004, 173:6921-6927.
28. Avirutnan P., Punyadee N., Noisakran S., Komoltri C., Thiemmeca S., Auethavornanan K., et al. Vascular leakage in severe dengue virus infections: a potential role for the nonstructural viral protein NS1 and complement. J Infect Dis 2006, 193:1078-1088.
29. Lachmann P.J., Hughes-Jones N.C. Initiation of complement activation. Springer Semin Immunopathol 1984, 7:143-162.
30. Silverberg M., Dunn J.T., Garen L., Kaplan A.P. Autoactivation of human Hageman factor Demonstration utilizing a synthetic substrate. J Biol Chem 1980, 255:7281-7286.
31. Ziccardi R.J. A new role for C-1-inhibitor in homeostasis: control of activation of the first component of human complement. J Immunol 1982, 128:2505-2508.
32. Kasahara Y., Odai H., Takahashi K., Nagasawa S., Koyama J. Autocatalytic activation of C1r subcomponent of the first component of human complement. J Biochem 1985, 97:365-372.
33. Ratnoff O.D., Pensky J., Ogston D., Naff G.B. The inhibition of plasmin, plasma kallikrein, plasma permeability factor, and the C'1r subcomponent of the first component of complement by serum C'1 esterase inhibitor. J Exp Med 1969, 129:315-331.
34. Kaplan A.P. Mechanisms of bradykinin generation. Urticaria and angioedema 2009, 73-90. Marcel Decker Inc., New York. M.W. Greaves, A.P. Kaplan (Eds.).
35. Vigler M., Lee S.K., Palti R., Williams J.C., Kaminsky A.J., Posner M.A., et al. Biomechanical comparison of techniques to reduce the bulk of lacerated flexor tendon ends within digital sheaths of the porcine forelimb. J Hand Surg Am 2009, 34:1653-1658.
36. Regoli D., Barabe J. Pharmacology of bradykinin and related kinins. Pharmacol Rev 1980, 32:1-46.
37. Mori K., Nagasawa S. Studies on human high molecular weight (HMW) kininogen. II. Structural change of HMW kininogen by the action of human plasma kallikrein. J Biochem 1981, 89:1465-1473.
38. Bhoola K.D., Figueroa C.D., Worthy K. Bioregulation of kinins: kallikreins, kininogens, and kininases. Pharmacol Rev 1992, 44:1-80.
39. Margolius H.S. Tissue kallikreins structure, regulation, and participation in mammalian physiology and disease. Clin Rev Allergy Immunol 1998, 16:337-349.
40. Erdos E.G., Sloane E.M. An enzyme in human blood plasma that inactivates bradykinin and kallidins. Biochem Pharmacol 1962, 11:585-592.
41. Sheikh I.A., Kaplan A.P. Studies of the digestion of bradykinin, lysyl bradykinin, and kinin-degradation products by carboxypeptidases A, B, and N. Biochem Pharmacol 1986, 35:1957-1963.
42. Yang H.Y., Erdos E.G. Second kininase in human blood plasma. Nature 1967, 215:1402-1403.
43. D'Orleans-Juste P., de Nucci G., Vane J.R. Kinins act on B1 or B2 receptors to release conjointly endothelium-derived relaxing factor and prostacyclin from bovine aortic endothelial cells. Br J Pharmacol 1989, 96:920-926.
44. Duchene J., Lecomte F., Ahmed S., Cayla C., Pesquero J., Bader M., et al. A novel inflammatory pathway involved in leukocyte recruitment: role for the kinin B1 receptor and the chemokine CXCL5. J Immunol 2007, 179:4849-4856.
45. Ghebrehiwet B., Lim B.L., Peerschke E.I., Willis A.C., Reid K.B. Isolation, cDNA cloning, and overexpression of a 33-kD cell surface glycoprotein that binds to the globular " heads" of C1q. J Exp Med 1994, 179:1809-1821.
46. Joseph K., Ghebrehiwet B., Peerschke E.I., Reid K.B., Kaplan A.P. Identification of the zinc-dependent endothelial cell binding protein for high molecular weight kininogen and factor XII: identity with the receptor that binds to the globular " heads" of C1q (gC1q-R). Proc Natl Acad Sci USA 1996, 93:8552-8557.
47. Herwald H., Dedio J., Kellner R., Loos M., Muller-Esterl W. Isolation and characterization of the kininogen-binding protein p33 from endothelial cells identity with the gC1q receptor. J Biol Chem 1996, 271:13040-13047.
48. Hasan A.A., Zisman T., Schmaier A.H. Identification of cytokeratin 1 as a binding protein and presentation receptor for kininogens on endothelial cells. Proc Natl Acad Sci USA 1998, 95:3615-3620.
49. Joseph K., Ghebrehiwet B., Kaplan A.P. Cytokeratin 1 and gC1qR mediate high molecular weight kininogen binding to endothelial cells. Clin Immunol 1999, 92:246-255.
50. Colman R.W., Pixley R.A., Najamunnisa S., Yan W., Wang J., Mazar A., et al. Binding of high molecular weight kininogen to human endothelial cells is mediated via a site within domains 2 and 3 of the urokinase receptor. J Clin Invest 1997, 100:1481-1487.
51. Joseph K., Tholanikunnel B.G., Ghebrehiwet B., Kaplan A.P. Interaction of high molecular weight kininogen binding proteins on endothelial cells. Thromb Haemost 2004, 91:61-70.
52. Hasan A.A., Cines D.B., Herwald H., Schmaier A.H., Muller-Esterl W. Mapping the cell binding site on high molecular weight kininogen domain 5. J Biol Chem 1995, 270:19256-19261.
53. Pixley R.J., Espinola R.G., Ghebrehiwet B., Joseph K., Kao A., Cines D.B., et al. Interaction of high molecular weight kininogen with endothelial cell binding proteins uPAR, gC1qR and cytokeratin 1 determined by plasmon resonance (BiaCore). Thromb Hemost 2011, 105:1053-1059.
54. Ghebrehiwet B., Lu P.D., Zhang W., Lim B.L., Eggleton P., Leigh L.E., et al. Identification of functional domains on gC1Q-R, a cell surface protein that binds to the globular " heads" of C1Q, using monoclonal antibodies and synthetic peptides. Hybridoma 1996, 15:333-342.
55. Gao B.B., Clermont A., Rook S., Fonda S.J., Srinivasan V.J., Wojtkowski M., et al. Extracellular carbonic anhydrase mediates hemorrhagic retinal and cerebral vascular permeability through prekallikrein activation. Nat Med 2007, 13:181-188.
56. Su J., Cui M., Tang Y., Zhou H., Liu L., Dong Q. Blockade of bradykinin B2 receptor more effectively reduces postischemic blood-brain barrier disruption and cytokines release than B1 receptor inhibition. Biochem Biophys Res Commun 2009, 388:205-211.
57. Merino V.F., Todiras M., Campos L.A., Saul V., Popova E., Baltatu O.C., et al. Increased susceptibility to endotoxic shock in transgenic rats with endothelial overexpression of kinin B(1) receptors. J Mol Med 2008, 86:791-798.
58. Cruwys S.C., Garrett N.E., Perkins M.N., Blake D.R., Kidd B.L. The role of bradykinin B1 receptors in the maintenance of intra-articular plasma extravasation in chronic antigen-induced arthritis. Br J Pharmacol 1994, 113:940-944.
59. Maeda H., Wu J., Okamoto T., Maruo K., Akaike T. Kallikrein-kinin in infection and cancer. Immunopharmacology 1999, 43:115-128.
60. Shariat-Madar Z., Mahdi F., Schmaier A.H. Assembly and activation of the plasma kallikrein/kinin system: a new interpretation. Int Immunopharmacol 2002, 2:1841-1849.
61. Davis A.E. The pathophysiology of hereditary angioedema. Clin Immunol 2005, 114:3-9.
62. Mahdi F., Madar Z.S., Figueroa C.D., Schmaier A.H. Factor XII interacts with the multiprotein assembly of urokinase plasminogen activator receptor, gC1qR, and cytokeratin 1 on endothelial cell membranes. Blood 2002, 99:3585-3596.
63. Shariat-Madar Z., Mahdi F., Schmaier A.H. Identification and characterization of prolylcarboxypeptidase as an endothelial cell prekallikrein activator. J Biol Chem 2002, 277:17962-17969.
64. Beltrani V.S. Angioedema: some new thoughts regarding idiopatic angioedema. Urticaria and angioedema 2004, 421-439. Marcel Dekker Inc., New York. M.V. Greaves, A.P. Kaplan (Eds.).
65. Davis A.E. C1 inhibitor gene and hereditary angioedema. The human complement system in health and disease 1998, 455-480. Marcel Dekker Inc., New York. E. Volanakis, M. Frank (Eds.).
66. Petersen S.V., Thiel S., Jensen L., Vorup-Jensen T., Koch C., Jensenius J.C. Control of the classical and the MBL pathway of complement activation. Mol Immunol 2000, 37:803-811.
67. Jiang H., Wagner E., Zhang H., Frank M.M. Complement 1 inhibitor is a regulator of the alternative complement pathway. J Exp Med 2001, 194:1609-1616.
68. Kaplan A.P. C1 inhibitor deficiency. Urticaria and angioedema 2004, 303-320. Marcel Dekker Inc., New York. M.V. Greaves, A.P. Kaplan (Eds.).
69. Nussberger J., Cugno M., Amstutz C., Cicardi M., Pellacani A., Agostoni A. Plasma bradykinin in angio-oedema. Lancet 1998, 351:1693-1697.
70. Donaldson V.H., Rosen F.S., Bing D.H. Role of the second component of complement (C2) and plasmin in kinin release in hereditary angioneurotic edema (H.A.N.E.) plasma. Trans Assoc Am Physicians 1977, 90:174-183.
71. Nielsen E.W., Johansen H.T., Hogasen K., Wuillemin W., Hack C.E., Mollnes T.E. Activation of the complement, coagulation, fibrinolytic and kallikrein-kinin systems during attacks of hereditary angioedema. Immunopharmacology 1996, 33:359-360.
72. Cicardi M., Banerji A., Bracho F., Malbran A., Rosenkranz B., Riedl M., et al. Icatibant, a new bradykinin-receptor antagonist, in hereditary angioedema. N Engl J Med 2010, 363:532-541.
73. Bossi F., Fischetti F., Regoli D., Durigutto P., Frossi B., Gobeil F., et al. Novel pathogenic mechanism and therapeutic approaches to angioedema associated with C1 inhibitor deficiency. J Allergy Clin Immunol 2009, 124:1303-1310. e1304.